Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia

Goren, Andy; Castaño, J; Ma, John; Bermúdez, Fernando; Lotti, Torello

doi:10.1111/dth.12111

Cited by 44 publications

(55 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from 70 patients was used in meta‐analysis (55 patients from two previously published studies and 15 patients from our ongoing study). All patients were treated with 5% minoxidil therapy (twice daily) for a minimum duration of 6 months.…”

Section: Methodsmentioning

confidence: 99%

“…All patients were treated with 5% minoxidil therapy (twice daily) for a minimum duration of 6 months. The sex and distribution of hair loss was not available in all cases and was not included in our analysis. Minoxidil response was determined, in all cases by blinded assessment of global photography.…”

Section: Methodsmentioning

confidence: 99%

“…Minoxidil is converted to its active form, minoxidil sulfate, in the outer root sheath of the hair follicle by endogenous sulfotransferase enzymes . Previously, two studies have reported a correlation between sulfotransferase activity in plucked hair follicles and minoxidil response for AGA patients . Combined data from both studies demonstrates the diagnostic is 94% sensitive and 76% specific for predicting response to minoxidil treatment for AGA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical utility and validity of minoxidil response testing in androgenetic alopecia

et al. 2014

Self Cite

View full text Add to dashboard Cite

Clinical response to 5% topical minoxidil for the treatment of androgenetic alopecia (AGA) is typically observed after 3-6 months. Approximately 40% of patients will regrow hair. Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts a patient's response to topical minoxidil therapy. The aim of this study was to assess the clinical utility and validity of minoxidil response testing. In this communication, the present authors conducted an analysis of completed and ongoing studies of minoxidil response testing. The analysis confirmed the clinical utility of a sulfotransferase enzyme test in successfully ruling out 95.9% of nonresponders to topical minoxidil for the treatment of AGA.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical utility and validity of minoxidil response testing in androgenetic alopecia

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…[27]. Реакция превращения миноксидила в миноксидила сульфат была сопряжена с реакцией выработки паранитрофенола, которая могла быть определена количественно с помощью оптического поглощения при 405 нм.…”

Section: как это работает?unclassified

Minoxidil: a final judgment or a hope?

Gadzhigoroeva¹

2016

Klin. dermatol. venerol.

View full text Add to dashboard Cite

ооо «Институт Красивых волос», Москва, Россия, 105082Миноксидил является базовым препаратом для наружной терапии андрогенетической алопеции у мужчин и женщин. Между тем отношение к миноксидилу неоднозначно как среди пациентов, так и среди врачей. недостаточное понимание этиологии разных форм потери волос, отсутствие ясности в механизмах интеракции миноксидила с клетками-мишенями, в особенности с клетками волосяного фолликула, а также специфичность реакции самих волос на ранних этапах лечения компрометирует действие препарата на волосы и организм человека в целом, ограничивая терапевтические возможности при лечении облысения, снижает комплаентность лечению у пациента. в статье приводится обзор научных исследований о стимулирующих механизмах миноксидила на рост волос, о клинической эффективности и преимуществе использования лекарственной формы препарата в виде пены при андрогенетической алопеции.Ключевые слова: миноксидил, пена миноксидил, андрогенетическая алопеция, лечение. Minoxidil: a final judgment or a hope?A.g. gADzHIgoRoEvA «Institute of nice Hair», Moscow, Russia, 105082Minoxidil is a basic drug for the topical treatment of androgenetic alopecia in males and females. Meanwhile, the attitude of both patients and medical professionals to minoxidil is controversial. Insufficient understanding of the etiology of various forms of hair loss, lack of clear understanding of the mechanisms of interaction between minoxidil and target cells, particularly the hair follicle cells, as well as specific reactions of the hair itself at the early stages of treatment, compromise drug effect on the hair and the entire human body, which results in limited therapeutic potential in treatment of hair loss and reduces patients' compliance. This article provides an overview of the research of stimulatory mechanisms of minoxidil on hair growth, clinical efficacy and benefits of the use of foam-like dosage form of the drug in patients with androgenetic alopecia.

show abstract

“…MXS represents an alternative with advantage over MX in individuals with low MX sulfotransferase activity, since the demonstration of an association between MX response and the degree of MX sulfatation [8]. However, in order to compensate such decreased response, MXS would have to be used at higher concentrations (10-15%) due to its decreased capacity of transcutaneous absorption and packaged in small volumes, because of its high degree of degradation.…”

mentioning

confidence: 99%

Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe?

Dias

Miot

Trüeb

et al. 2018

Skin Appendage Disord

View full text Add to dashboard Cite

In Brazil, alternatively, there has been a rise in the prescription and use of MXS-based formulations due to its pharmaceutical solubility [6,7]. However, in addition to the issue of its higher molecular weight, MXS is naturally unstable in aqueous solution, negatively affecting its bioavailability to the hair follicle and increasing its irritation potential to the scalp. Therefore, efficacy of MXS compared to MX base for the treatment of AGA may be impaired, and the same efficacy may not be expected as in the original clinical trials with MX base.The MX sulfotransferase activity is not the same in every individual. MXS represents an alternative with advantage over MX in individuals with low MX sulfotransferase activity, since the demonstration of an association between MX response and the degree of MX sulfatation [8]. However, in order to compensate such decreased response, MXS would have to be used at higher concentrations (10-15%) due to its decreased capacity of transcutaneous absorption and packaged in small volumes, because of its high degree of degradation.Indeed, a Swiss retrospective study of 44 patients with AGA (13 males with Hamilton-Norwood type AGA class III or above and 31 females with Ludwig type AGA I-III) unresponsive to a minimum of 6 months of 5% MX solution b.i.d. showed increase in hair growth in 97.7% using a 10% MXS solution once daily during a mean treatment period of 4.09 months. The treatment was well tolerated by patients, among whom 6.8% suffered from irritation, erythema, and folliculitis of the scalp. No major adverse effect was noted [9].We aim to emphasize the differences between topical formulations of MX and MXS available on the Brazilian market, i.e., penetration and stability issues for MXS formulations, and the problem of low sulfotransferase activity for MX prescriptions. Our opinion is that topical MX base remains the first-line topical agent for treatment of male and female AGA, unless the patient proves to be unresponsive, then a formulation of MXS at probably higher concentrations may present an alternative with enhanced efficacy. For this purpose, a novel enzymatic assay may predict MX response [10].Comparative clinical trials and pharmacological studies with different formulations, either ready for use or custom made, with MX base or MXS, should be conducted in order to make final recommendations for optimal use in AGA treatment. Disclosure StatementThe authors have no conflicts of interest to disclose. Dear Editors,Androgenetic alopecia (AGA) represents an important cause of hair loss affecting 73% of men and 57% of women until the age of 80 years [1][2][3], with an age-dependent increase in frequency, and the perspective of rising incidence due to a general increase in life expectancy [2]. Due to its emotional impact with a negative effect on patient's quality of life, it is important to establish an early diagnosis and treatment plan in order to avoid progression of hair loss.The drugs currently available for treatment of AGA with approval of the US Food and Drug A...

show abstract

Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia

Cited by 44 publications

References 4 publications

Clinical utility and validity of minoxidil response testing in androgenetic alopecia

Clinical utility and validity of minoxidil response testing in androgenetic alopecia

Minoxidil: a final judgment or a hope?

Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe?

Contact Info

Product

Resources

About